SLC5A2 and diabetic kidney disease: Zn association further potentiated these effects, with the most pronounced benefits observed when combined with EMPA.<h4>Conclusions</h4>These findings suggest that SGLT2 inhibitors exert strong renoprotective effects in experimental diabetic nephropathy.